{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:48:13Z","timestamp":1791470893915,"version":"4.3.4"},"reference-count":76,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>The phenotype of an attenuated live vaccine depends on gene mutation achieved by, for example, many passages in cultured cells. Viral clones with preferable phenotypes are selected and the causative genetic mutation(s) are later identified. LC16m8 is an example of a highly attenuated smallpox vaccine that was developed and licensed in Japan in the 1970s. LC16m8 was obtained by the passaging of Lister strain, with indicators of small plaque formation and temperature sensitivity as virus phenotypes. This strain can replicate in mammalian cells and provides robust cellular and humoral immunity, as well as long-term immune memory. Recent studies using proteome-wide antigen arrays have revealed that antibody production against LC16m8 and other VACVs differs largely among individuals. Moreover, associations between SNPs in immune-related genes and immune outcomes have been increasingly found. These results lead to predicting adverse events of a vaccine, which is a purpose of vaccinomics. Studies on VACV will continue to contribute to the understanding of host-pathogen interactions and to development of a vaccine for other infectious and non-infectious diseases. Here, we review studies of VACV, including our recent research on LC16m8, with a focus on the phenotype and genotype, and we discuss future research directions.<\/jats:p>","DOI":"10.3390\/biology10111158","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T10:44:58Z","timestamp":1636454698000},"page":"1158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain"],"prefix":"10.3390","volume":"10","author":[{"given":"Akiko","family":"Eto","sequence":"first","affiliation":[{"name":"Department of Health Crisis Management, National Institute of Public Health, 2-3-6 Minami Wako, Saitama 351-0193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Virology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-4084","authenticated-orcid":false,"given":"Yasuhiro","family":"Kanatani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/21645515.2018.1476813","article-title":"The Human Vaccines Project: Towards a comprehensive understanding of the human immune response to immunization","volume":"14","author":"Wooden","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.clpt.6100415","article-title":"Heterogeneity in Vaccine Immune Response: The Role of Immunogenetics and the Emerging Field of Vaccinomics","volume":"82","author":"Poland","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"ref_4","unstructured":"Quinnan, G.V. (1985). Properties of Attenuated Mutant of Vaccinia Virus; LC16m8; Derived from Lister Strain. Vaccinia Viruses as Vectors for Vaccine Antigens, Elsevier Science Publishing Co. Inc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: An attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1099\/0022-1317-68-10-2705","article-title":"Genetic Analysis of Vaccinia Virus Lister Strain and its Attenuated Mutant LC16m8: Production of Intermediate Variants by Homologous Recombination","volume":"68","author":"Suzuki","year":"1987","journal-title":"J. Gen. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0042-6822(91)90480-Y","article-title":"Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins","volume":"181","author":"Funahashi","year":"1991","journal-title":"Virology"},{"key":"ref_8","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Eradication, World Health Organization. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/39485."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1128\/jvi.66.12.7217-7224.1992","article-title":"Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope","volume":"66","author":"Isaacs","year":"1992","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","article-title":"A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope","volume":"188","author":"Engelstad","year":"1992","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An Attenuated LC16m8 Smallpox Vaccine: Analysis of Full-Genome Sequence and Induction of Immune Protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1016\/j.vaccine.2015.07.111","article-title":"Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8","volume":"33","author":"Eto","year":"2015","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000\u2122: The new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/JVI.02089-12","article-title":"Humoral Immunity to Smallpox Vaccines and Monkeypox Virus Challenge: Proteomic Assessment and Clinical Correlations","volume":"87","author":"Townsend","year":"2013","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/j.vaccine.2019.09.006","article-title":"Profiling of the antibody response to attenuated LC16m8 smallpox vaccine using protein array analysis","volume":"37","author":"Eto","year":"2019","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, value in basic research and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, R., Mendez-Rios, J.D., Peng, C., Xiao, W., Weisberg, A.S., Wyatt, L.S., and Moss, B. (2019). SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007710"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of Extracellular Enveloped Virus in the in vitro and in vivo Dissemination of Vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J. Gen. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.1183173","article-title":"Repulsion of Superinfecting Virions: A Mechanism for Rapid Virus Spread","volume":"327","author":"Doceul","year":"2010","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.vaccine.2011.08.116","article-title":"Vaccinia virus-induced smallpox postvaccinal encephalitis in case of blood\u2013brain barrier damage","volume":"30","author":"Garcel","year":"2012","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.vaccine.2003.10.022","article-title":"Mouse neurotoxicity test for vaccinia-based smallpox vaccines","volume":"22","author":"Li","year":"2004","journal-title":"Vaccine"},{"key":"ref_27","first-page":"41","article-title":"Effort to improve smallpox vaccine. Rinsho to Uirusu","volume":"24","author":"Kitamura","year":"1996","journal-title":"Clin. Virus."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.molimm.2008.12.016","article-title":"In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R","volume":"46","author":"Sirven","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1128\/JVI.00601-06","article-title":"Human T-Cell Responses to Vaccinia Virus Envelope Proteins","volume":"80","author":"Tang","year":"2006","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R","volume":"79","author":"Whitbeck","year":"2005","journal-title":"J. Virol."},{"key":"ref_31","unstructured":"Immune Epitope Database and Analysis Resource (2021, September 14). IEDB Website. Available online: https:\/\/www.iedb.org."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2018","journal-title":"Nucl. Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1016\/j.vaccine.2015.07.076","article-title":"Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice","volume":"33","author":"Yokote","year":"2015","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults","volume":"204","author":"Kennedy","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1016\/j.vaccine.2015.09.067","article-title":"Freeze-dried live attenuated smallpox vaccine prepared in cell culture \u201cLC16-KAKETSUKEN\u201d: Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice","volume":"33","author":"Nishiyama","year":"2015","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/382510","article-title":"Adverse Events after Smallpox Immunizations Are Associated with Alterations in Systemic Cytokine Levels","volume":"189","author":"Rock","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.4049\/jimmunol.1500106","article-title":"IL-1R Type 1\u2013Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection","volume":"198","author":"Tian","year":"2017","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.gene.2012.08.021","article-title":"Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination","volume":"510","author":"Ovsyannikova","year":"2012","journal-title":"Gene"},{"key":"ref_39","first-page":"1403","article-title":"Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients","volume":"131","author":"Kennedy","year":"2012","journal-title":"Qual. Life Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/518794","article-title":"The Immunogenetics of Smallpox Vaccination","volume":"196","author":"Stanley","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/588670","article-title":"Genetic Basis for Adverse Events after Smallpox Vaccination","volume":"198","author":"Reif","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/gene.2008.80","article-title":"Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination","volume":"10","author":"Reif","year":"2008","journal-title":"Genes Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: Targets of protective immunity","volume":"239","author":"Moss","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virol.2005.08.008","article-title":"Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin","volume":"343","author":"Garcia","year":"2005","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","article-title":"Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections","volume":"167","author":"Gilchuk","year":"2016","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and Protective Antibodies Directed against Vaccinia Virus Envelope Antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","article-title":"Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery","volume":"102","author":"Davies","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox","volume":"7","author":"Davies","year":"2007","journal-title":"Proteomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine","volume":"82","author":"Benhnia","year":"2008","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/prca.200780113","article-title":"Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome","volume":"2","author":"Schmid","year":"2008","journal-title":"Proteom.-Clin. Appl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.vaccine.2008.12.035","article-title":"The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays","volume":"27","author":"Wollenick","year":"2009","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Keasey, S., Pugh, C., Tikhonov, A., Chen, G., Schweitzer, B., Nalca, A., and Ulrich, R.G. (2010). Proteomic Basis of the Antibody Response to Monkeypox Virus Infection Examined in Cynomolgus Macaques and a Comparison to Human Smallpox Vaccination. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015547"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.vaccine.2011.11.021","article-title":"Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax\u00ae using proteome microarrays and development of recombinant protein ELISAs","volume":"30","author":"Hermanson","year":"2012","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/CVI.05521-11","article-title":"Failure of the Smallpox Vaccine To Develop a Skin Lesion in Vaccinia Virus-Na\u00efve Individuals Is Related to Differences in Antibody Profiles before Vaccination, Not After","volume":"19","author":"Tan","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/CVI.00035-14","article-title":"Human Antibody Responses to the Polyclonal Dryvax Vaccine for Smallpox Prevention Can Be Distinguished from Responses to the Monoclonal Replacement Vaccine ACAM2000","volume":"21","author":"Pugh","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.2009.289","article-title":"Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8","volume":"301","author":"Saito","year":"2009","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1099\/vir.0.034207-0","article-title":"Serological responses in humans to the smallpox vaccine LC16m8","volume":"92","author":"Johnson","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_59","first-page":"1083","article-title":"HLA alleles associated with the adaptive immune response to smallpox vaccine: A replication study","volume":"133","author":"Ovsyannikova","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/infdis\/jir268","article-title":"Common SNPs\/Haplotypes in IL18R1 and IL18 Genes Are Associated With Variations in Humoral Immunity to Smallpox Vaccination in Caucasians and African Americans","volume":"204","author":"Haralambieva","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1016\/j.vaccine.2012.04.055","article-title":"Genome-wide association study of antibody response to smallpox vaccine","volume":"30","author":"Ovsyannikova","year":"2012","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.vaccine.2009.01.086","article-title":"Gender effects on humoral immune responses to smallpox vaccine","volume":"27","author":"Kennedy","year":"2009","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2013.03.042","article-title":"Reflections on the early development of poxvirus vectors","volume":"31","author":"Moss","year":"2013","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: A selectable eukaryotic cloning and expression vector","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1073\/pnas.79.16.4927","article-title":"Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus","volume":"79","author":"Panicali","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.11.79","article-title":"Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors","volume":"10","author":"Walsh","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(94)90215-1","article-title":"Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines","volume":"12","author":"Sugimoto","year":"1994","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/vaccines2040755","article-title":"Vaccinia Virus LC16m8\u2206 as a Vaccine Vector for Clinical Applications","volume":"2","author":"Kidokoro","year":"2014","journal-title":"Vaccines"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1016\/j.vaccine.2021.09.001","article-title":"Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers","volume":"39","author":"Yoshikawa","year":"2021","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/j.vaccine.2005.01.079","article-title":"A novel, cell culture-derived smallpox vaccine in vaccinia-na\u00efve adults","volume":"23","author":"Artenstein","year":"2005","journal-title":"Vaccine"},{"key":"ref_72","unstructured":"CDC (2021, September 14). Contraindication for Primary Vaccines and Revaccinees, Available online: https:\/\/www.cdc.gov\/smallpox\/clinicians\/vaccination-contraindications1.html."},{"key":"ref_73","unstructured":"World Health Organization (2014). Meeting of the Strategic Advisory Group of Experts on Immunization, November 2013\u2014Conclusions and Recommendations. Weekly Epidemiological Record = Relev\u00e9 \u00c9pid\u00e9miologique Hebdomadaire, WHO."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Overton, E.T., Lawrence, S.J., Wagner, E., Nopora, K., R\u00f6sch, S., Young, P., Schmidt, D., Kreusel, C., De Carli, S., and Meyer, T.P. (2018). Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195897"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Georgana, I., Sumner, R.P., Towers, G.J., and de Motes, C.M. (2018). Virulent Poxviruses Inhibit DNA Sensing by Preventing STING Activation. J. Virol., 92.","DOI":"10.1128\/JVI.02145-17"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/11\/1158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:11Z","timestamp":1760167691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/11\/1158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":76,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["biology10111158"],"URL":"https:\/\/doi.org\/10.3390\/biology10111158","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}